07:59 AM EDT, 06/03/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Monday that its experimental drug, TAK-861, to treat narcolepsy type 1 demonstrated "statistically significant and clinically meaningful" improvements across primary and secondary endpoints in a phase 2b trial.

The treatment demonstrated increases in sleep latency on the maintenance of wakefulness test versus placebo sustained over 8 weeks, the company said.

TAK-861 was generally safe and well tolerated during the study, with no treatment-related severe adverse events, Takeda said.

Takeda said it plans to initiate global phase 3 trials of TAK-861 in the first half of fiscal year 2024.

Price: 13.39, Change: +0.04, Percent Change: +0.30